MIRA Pharmaceuticals Unveils Ketamir-2’s Principal Metabolite: Nor-Ketamir – a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA Pharmaceuticals, a leading pre-clinical-stage pharmaceutical...
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
<p><i><strong>Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog</strong></i></p> MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA"...